…significantly extended lifespan in Caenorhabditis elegans, a simple model organism. KDM1A’s anti-cancer activities have already been established in both preclinical and clinical studies, including in colorectal and triple negative breast…
…a central role in pain signalling, in part through the release of neurotransmitters such as glutamate and GABA. The Cav2.2 (or N-type) calcium channel is the target for three clinically…
…showed that Verve-101 could meaningfully and durably lower LDL-C in these patients. We’re at an exciting moment for cardiovascular prevention where the management of ASCVD may fundamentally change.” heart-1 clinical…
…they sequenced the genomes of 85 S. Typhi samples obtained from people with confirmed typhoid fever from 2012 to 2019, plus an extra 10 from clinical infections in the UK…
…Review. It was approved under accelerated approval based on anti-CHIKV neutralising antibody titers and is contingent upon verification of clinical benefit in confirmatory studies. “Infection with chikungunya virus can lead…
…alliance to strengthen early clinical oncology research Cancer Research UK and the KWF Dutch Cancer Society (KWF) have announced a new multi-project strategic partnership to advance promising therapeutic agents for…
Topline results from a Phase I/II clinical trial have shown that Kiora’s light-restoring small molecule KIO-301 has the potential to meaningfully improve vision in patients with retinitis pigmentosa (RP). The…
Researchers from Korea conducted a clinical trial to assess the immunogenicity and safety of GBP510/AS03 relative to the ChAdOx1-S vaccine. The interim results show that GBP510/AS03 had an acceptable safety…
…from this clinical study to date provides important initial evidence that SNS-101 can provide clinically meaningful and mechanistic differentiation from first generation anti-VISTA approaches, as indicated by SNS-101 dose levels…
…efficacy observed in a prior Phase IIa proof of concept (POC) study of apimostinel, validating the biomarker for informing dose selection in future clinical efficacy studies across the class of…
…of action, signals the emergence of a promising new approach to treatment. I am confident that future Phase III trials will further validate these findings, ultimately granting patients access to…
Oxeia Biopharmaceuticals, a clinical stage biotech company developing a drug treatment for concussion to address underlying neuro-metabolic dysfunction and axonal injury, has announced “game-changing” results of a Phase IIa pilot…
…in Queensland,” Dr Mercer said. “We aim to begin manufacturing mRNA for Phase I clinical trials in 2024.” Vice-Chancellor Professor Deborah Terry added that having the capability to produce clinical…
…on the latest industry updates. The news highlights this week feature a variety of exciting clinical trial results and launches that are examining therapies for much-needed disease areas, new drug…
…clinical trials. We look forward to strengthening early clinical oncology research on an international level and are thrilled to see what the future holds for improving therapeutic strategies for patients.”…
